Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3710 results
Evotec, Eternygen to discover and develop new metabolic disease therapy
By PBR Staff Writer
German pharmaceutical firms Evotec and Eternygen have entered into a drug discovery collaboration to develop new small molecule inhibitors.
Drug Research > Drug Discovery & Development > News
Regeneron, Avalanche to develop new gene therapy products in ophthalmology
By PBR Staff Writer
Regeneron Pharmaceuticals and Avalanche Biotechnologies have formed a broad collaboration to discover, develop and commercialize new gene therapy products for the treatment of ophthalmologic diseases.
Drug Research > Drug Discovery & Development > News
Auven Therapeutics, Bellus Health announce license agreement with Mount Sinai for Kiacta in sarcoidosis
Auven Therapeutics and Bellus Health have announced that Auven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which the company obtains rights to develop Kiacta (eprodisate) as a treatment for chronic sarcoidosis.
Drug Research > Drug Discovery & Development > News
DSMB recommends stopping Vintafolide PROCEED Phase III trial
Merck and Endocyte have announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of progression-free survival (PFS) in patients with platinum-resistant ovarian cancer.
Drug Research > Drug Discovery & Development > News
FDA issues complete response letter for Plumiaz
Acorda Therapeutics has announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for Plumiaz (diazepam) nasal spray for the treatment of people with epilepsy who experience cluster seizures.
Drug Research > Drug Discovery & Development > News
Ruthigen submits IND application to FDA for Phase I/II clinical trial of RUT58-60
By PBR Staff Writer
Ruthigen has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for clinical trial of RUT58-60, a new chemical formulation containing hypochlorous acid (HOCl) with no hypochlorite that utilizes other small molecule stabilizers such as magnesium.
Drug Research > Drug Discovery & Development > News
ANI Pharma, Sofgen Pharma sign agreement to develop ANDA soft gel oral drug product
By PBR Staff Writer
ANI Pharmaceuticals, an integrated specialty pharmaceutical company, and Sofgen Pharmaceuticals, a niche pharmaceutical company, have signed an exclusive licensing, development and supply agreement for the development of an ANDA soft gel oral drug product.
Drug Research > Drug Discovery & Development > News
Merrimack Pharma announces MM-398 achieves primary endpoint in Phase III study
Merrimack Pharmaceuticals has announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.
Drug Research > Drug Discovery & Development > News
Nova Laboratories receives FDA approval for acute lymphoblastic leukemia drug
By PBR Staff Writer
UK-based Nova Laboratories has received approval from the US Food and Drug Administration (FDA) for its acute lymphoblastic leukemia (ALL) drug Xaluprine, which will be marketed as Purixan in the US.
Drug Research > Drug Discovery & Development > News
Advaxis receives Orphan Drug Designation from FDA for cervical cancer drug
By PBR Staff Writer
Advaxis, a clinical-stage biotechnology company, has received Orphan Drug Designation from the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV for the treatment of Stage II-IV invasive cervical cancer.
Drug Research > Drug Discovery & Development > News
Theratechnologies regains commercialization rights of EGRIFTA in Canada
By PBR Staff Writer
Canadian pharmaceutical firm Theratechnologies has received regulatory approval from Health Canada for EGRIFTA (tesamorelin for injection).
Drug Research > Drug Discovery & Development > News
Cannabis Science, MEDIWIET to conduct clinical observational study in Netherlands
By PBR Staff Writer
Cannabis Science (CBIS), a US-based firm specializing in the development of cannabis based medicines, has entered into an agreement with MEDIWIET Patient Organization to carry out a joint observational trial in the Netherlands.
Drug Research > Drug Discovery & Development > News
DOD recommends funding for Neumedicines' Phase I study of recombinant human interleukin-12
Neumedicines has announced that their proposal to conduct a Phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP).
Drug Research > Drug Discovery & Development > News
Diaxonhit receives financing from Bpifrance to develop companion diagnostic for therapeutic vaccine against AIDS
Diaxonhit has announced that it was granted approximately €1.73m by Bpifrance, as part of its involvement in a research consortium led by InnaVirVax and funded under the program for ‘Strategic Industrial Innovation’.
Drug Research > Drug Discovery & Development > News
Agendia, Daiichi Sankyo collaborate on oncology drug development
By PBR Staff Writer
Agendia has entered into a new agreement with Japanese pharmaceutical firm Daiichi Sankyo regarding oncology drug development and personalized medicine.
Drug Research > Drug Discovery & Development > News
61-75 of 3710 results